BJC reports最新文献

{"title":"Role of consolidative surgery after chemotherapy in recurrent/metastatic adrenal cortical cancer (ACC): Princess Margaret Cancer Centre experience.","authors":"Abhenil Mittal, Lama Amer, Olubukola Ayodele, Suhaib Radi, Xuan Li, Daniel Vilarim Araujo, Eoghan Ruadh Malone, Esmail Mutahar Al-Ezzi, Jesse Pasternak, Ozgur Mete, Di Maria Jiang, Vikaash Kumar, Anthony M Joshua, Shereen Ezzat, Aaron Richard Hansen","doi":"10.1038/s44276-026-00237-7","DOIUrl":"10.1038/s44276-026-00237-7","url":null,"abstract":"<p><strong>Background: </strong>Recurrent/Metastatic (R/M) ACC is aggressive with few effective treatment options. The role of surgery after chemotherapy remains unclear. Moreover, prognostic factors in R/M ACC are not well defined.</p><p><strong>Methods: </strong>R/M ACC patients treated at Princess Margaret Cancer Centre (2002-2019) were retrospectively reviewed. Descriptive statistics were used to summarize clinical characteristics. OS was estimated by Kaplan-Meier method. Cox regression analysis was used to compute prognostic variables.</p><p><strong>Results: </strong>Among 83 patients with metastatic ACC [36.2% de novo and 63.8% recurrent], 49 (59.0%) received systemic therapy (ST) with which 15 (30.6%) had a partial response (PR) and 8 (16.3%) had stable disease (SD). 9 (18.4%) had surgery after ST (combined therapy group); 6 (66.6%) were rendered disease free with surgery. The median OS was 26 months (20.4-40.5) for entire cohort (f/up 18 months). OS for patients having combined therapy was 31.2 months (21.4-63.3) vs 24.7 months (17.7-35.2), p = 0.48 for patients receiving systemic therapy alone. Being disease free after surgery was associated with better OS [39.6 (24.8-not reached), vs 23.5 months (21.4-not reached), p = 0.02].</p><p><strong>Conclusions: </strong>Selected patients with R/M ACC may achieve long term survival with surgery after chemotherapy. These data highlight the potential role for multimodal therapy in managing such patients.</p>","PeriodicalId":519964,"journal":{"name":"BJC reports","volume":"4 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13433932/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148671707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Peribronchial cuffing: an underrecognized pattern of prostate carcinoma metastases to the lung.","authors":"Timothy W Miller, Susan F Slovin, Rania G Aly, Natasha Rekhtman, Xiaoyue Ma, Mateus De Oliveira Taveira, Ali Aria Razmaria, Or Kalchiem-Dekel","doi":"10.1038/s44276-026-00240-y","DOIUrl":"10.1038/s44276-026-00240-y","url":null,"abstract":"<p><strong>Background: </strong>Prostate cancer is a leading cause of cancer-related morbidity and mortality in men, with a subset of patients developing aggressive, castrate-resistant disease. We describe an underrecognized pattern of thoracic metastasis - peribronchial cuffing - in patients with advanced prostate cancer, with the aim to elucidate clinical, radiographic, and pathologic features and thus facilitate early recognition and management.</p><p><strong>Methods: </strong>This was a retrospective case series conducted at a quaternary cancer center between February 2020 and June 2025. Patients with prostate cancer and radiographic evidence of peribronchial cuffing were identified through a multidisciplinary service review. Clinical data were abstracted, radiographic cross-sectional imaging findings were independently confirmed, pathologic specimens were revisited for histochemical staining with H-scoring, and next-generation sequencing results were analyzed.</p><p><strong>Results: </strong>A total of nine patients demonstrated lower lobe-predominant peribronchial thickening, with 78% exhibiting right-sided involvement. All lesions were FDG- and/or PSMA-avid on positron emission tomography studies. Mediastinal lymphadenopathy and parenchymal lung metastases were concomitantly present in 66 and 22% of patients, respectively. The median time from PSA rise from baseline to cross-sectional imaging was 12.9 months, and from imaging to biopsy was 3.8 months. Tumor TP53 gene alterations were found in 66% of cases. In 33% of patients, the diagnosis of peribranchial metastases resulted in cancer upstaging. On follow-up, 55% of patients died within a median of 5.3 months from radiographic detection.</p><p><strong>Conclusions: </strong>Peribronchial metastasis represents a rare and underrecognized pattern of advanced prostate cancer spread. Its subtle presentation may result in delays in diagnosis and treatment. Recognition of this pattern in patients with rising PSA can be facilitated by new-generation molecular PET imaging studies to guide earlier biopsy and treatment initiation. Future studies are needed to characterize the pathobiologic mechanisms underlying this form of prostate cancer metastasis.</p>","PeriodicalId":519964,"journal":{"name":"BJC reports","volume":"4 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13379588/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148475485","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term outcomes and GVHD in allogeneic hematopoietic cell transplantation abroad: a 14-year UAE multi-center cohort.","authors":"Naveed Syed, Mohamed Abuhaleeqa, Fatema Mohammed Al Kaabi, Naser Alzein, Zainul Aabideen, Aydah M Al-Awadhi, Arif Alam, Azmat Ali Khan, Imrana Afrooz, Farooq Ahmed Mir, Riad Alhasan, Moussab Damlaj, Osama Taher Anaam, Manar Hassan Mohamed, Gehad ElGhazali, Kayane Mheidly, Shahrukh Hashmi","doi":"10.1038/s44276-026-00239-5","DOIUrl":"10.1038/s44276-026-00239-5","url":null,"abstract":"<p><strong>Background: </strong>Hematopoietic cell transplant (HCT) data are well reported, but for cohorts transplanted abroad and returning to countries without transplant services, long-term outcomes such as chronic graft versus host disease (GVHD) and overall survival remain poorly captured, underscoring the need for longitudinal follow-up.</p><p><strong>Methods: </strong>We conducted a 14-year retrospective multi-center study of allogeneic HCT recipients followed at three tertiary hospitals in the United Arab Emirates(UAE). Transplant characteristics, conditioning, GVHD prophylaxis, and outcomes were abstracted from medical records. Crude survival was reported for all indications, Kaplan-Meier (KM) overall survival for diseases with ≥20 cases.</p><p><strong>Results: </strong>A total of 363 allogeneic HCTs were analyzed. Overall, cohort characteristics differed from those reported in the literature: adults undergoing HCT were relatively young, female predominance was observed in pediatric malignancies and immune deficiencies, and matched unrelated donor (MUD) utilization was limited, while peripheral blood stem cell use was higher than typically described. In contrast, haploidentical donor utilization, conditioning intensity, and GVHD prophylaxis patterns were broadly consistent with international practice. GVHD incidence was high:69.2% in adults; 45.7% in children. In adults with acute myeloid leukemia (AML), acute GVHD was associated with an inferior 5-year OS (p = 0.036). In pediatric AML, both acute-/chronic GVHD were linked to poor survival (<50%), while survival for acute lymphoblastic leukemia (B-/T-ALL) exceeded 85%. cGVHD worsened overall survival (OS) more in pediatrics than adults.</p><p><strong>Conclusions: </strong>Although most findings aligned with established benchmarks, the high GVHD incidence and its association with adverse outcomes highlight the need for improved prevention strategies and the development of local transplant services.</p>","PeriodicalId":519964,"journal":{"name":"BJC reports","volume":"4 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13369791/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148451319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Molecular subtypes and the (in vitro) response of glioblastoma to temozolomide.","authors":"Silvia Rancati, Matilde Campolungo, Gerusa Duarte Dalmolin, Pierre Lau, Federica Furia, Alessandro Coppe, Fabio Landuzzi, Manuela Vecchi, Andrea Cavalli, Stefano Gustincich, Nicola Tirelli","doi":"10.1038/s44276-026-00236-8","DOIUrl":"10.1038/s44276-026-00236-8","url":null,"abstract":"","PeriodicalId":519964,"journal":{"name":"BJC reports","volume":"4 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13291256/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148311119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biomass burning, PM2.5 peaks, and trends in lung adenocarcinoma diagnoses: an ecological study in São Paulo State, Brazil.","authors":"Saulo Brito Silva, Henrique Goldhart Larssen, Leandro Machado Colli","doi":"10.1038/s44276-026-00235-9","DOIUrl":"10.1038/s44276-026-00235-9","url":null,"abstract":"<p><strong>Background: </strong>Lung adenocarcinoma diagnoses have increased globally despite declining tobacco exposure, raising questions about non-tobacco-related contributors. The role of fine particulate matter (PM2.5) peaks related to biomass burning in shaping population-level lung cancer patterns remains unexplored.</p><p><strong>Methods: </strong>An ecological analysis was conducted across the Regional Health Departments of São Paulo State, Brazil, from 2000 to 2023. Histologically confirmed lung cancer cases were obtained from the state cancer registry. Temporal trends in the adenocarcinoma-to-total lung cancer ratio (ATR) were evaluated alongside annual mean and maximum PM2.5 concentrations and wildfire counts derived from satellite data.</p><p><strong>Results: </strong>Among 51,580 lung cancer cases, adenocarcinoma accounted for 36%. Regions with a significant increase in ATR demonstrated annual increases ranging from 0.39 to 0.72%. With the exception of the São Paulo metropolitan area, which showed high mean PM2.5 levels despite low wildfire activity, all other regions with increasing ATR exhibited substantially higher wildfire occurrence (311 vs. 207 annual hotspots; p = 0.049), which strongly correlated with PM2.5 peaks (ρ = 0.928, p = 0.007). Periods of elevated PM2.5 peaks consistently coincided with increased wildfire activity.</p><p><strong>Conclusions: </strong>These findings suggest that biomass-burning-related PM2.5 peaks may be relevant to population-level patterns of lung cancer epidemiology.</p>","PeriodicalId":519964,"journal":{"name":"BJC reports","volume":"4 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13291169/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148311134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcome measurement tools in pediatric oncology palliative care: a scoping review of domains, validation and contextual relevance.","authors":"Vani Verma, Arun Ghoshal, Mebin Mathew, Harshitha D, Aishwarya Sanian, Krithika S Rao, Vasudeva Bhat K, Naveen Salins","doi":"10.1038/s44276-026-00219-9","DOIUrl":"10.1038/s44276-026-00219-9","url":null,"abstract":"<p><p>Paediatric palliative care (PPC) in oncology plays a crucial role in enhancing the quality of life for children with cancer and their families. However, outcome measurement in this context remains fragmented, with tools often lacking validation, paediatric specificity, or contextual relevance, especially in low- and middle-income countries (LMICs). This scoping review maps the outcome measurement tools used in paediatric oncology palliative care, examining their assessed domains, psychometric properties and cultural, linguistic and health-system contextual relevance, particularly in LMICs. We systematically searched six databases from 2006 to 2025 and identified 27 eligible studies reporting on 28 unique tools across six key domains: symptom burden, quality of life, psychological well-being, spiritual health, caregiver burden and end-of-life care. While tools like Paediatric Quality of Life Inventory (PedsQL) and Symptom Screening in Pediatrics Tool (SSPedi) showed strong psychometric performance, only a few had been adapted for LMIC contexts. The psychological and spiritual domains were underrepresented, and most tools relied on proxy reporting, which limited child-centred assessments. The findings suggest the need for validated, culturally sensitive and inclusive tools co-developed with children and caregivers. Establishing such outcome measures is essential to ensuring equitable, high-quality palliative care across diverse settings. This review lays the groundwork for developing tools and advancing policies that support comprehensive and compassionate care for children with cancer. Review registration: The review is registered on Open Science Framework (OSF) https://doi.org/10.17605/OSF.IO/G8BN3 .</p>","PeriodicalId":519964,"journal":{"name":"BJC reports","volume":"4 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13273101/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148267789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic significance of intratumoral neutrophil extracellular traps in pulmonary pleomorphic carcinoma: comparison with adenocarcinoma.","authors":"Makoto Yoden, Ryosuke Kaku, Daigo Ishihara, Kohei Shibata, Keiko Ueda, Takuya Shiratori, Yoko Kataoka, Yo Kawaguchi, Jun Hanaoka, Fumihiro Shoji","doi":"10.1038/s44276-026-00234-w","DOIUrl":"10.1038/s44276-026-00234-w","url":null,"abstract":"<p><strong>Background: </strong>Pleomorphic carcinoma (PC) of the lung is a rare, aggressive non-small cell lung cancer. Neutrophil extracellular traps (NETs) are linked to tumour progression, but their relevance in pulmonary PC is unknown. We evaluated the prognostic impact of intratumoral NETs and CD66b⁺ neutrophil infiltration in PC versus adenocarcinoma.</p><p><strong>Methods: </strong>Among 1148 patients who underwent pulmonary resection for primary lung cancer, 813 patients with adenocarcinoma and 17 with PC were analysed. Clinicopathological factors and survival were compared and propensity score matching was applied. NETs and neutrophils were quantified by CD66b immunohistochemistry and citrullinated histone H3/myeloperoxidase immunofluorescence.</p><p><strong>Results: </strong>PC was associated with heavier smoking, more vascular invasion, and more advanced stage than adenocarcinoma (all p < 0.001). The patient characteristics were comparable after matching. Overall and recurrence-free survival were both worse in the PC group (both p < 0.001) and remained poorer after matching. Cox analysis identified NET-positive area (% per high-power field) as an independent predictor of worse overall survival (hazard ratio 1.14, 95% confidence interval 1.01-1.30; p = 0.033).</p><p><strong>Conclusions: </strong>Pulmonary PC shows intense neutrophil infiltration and abundant intratumoral NETs, both associated with poor survival. Quantitative assessment of NETs may serve as a biomarker and therapeutic target in PC.</p>","PeriodicalId":519964,"journal":{"name":"BJC reports","volume":"4 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13263318/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148240861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Duty of care: amplifying the impact of planetary health research at oncology conferences.","authors":"Seamus O'Reilly, Rob Chuter, Sara V Lightowlers","doi":"10.1038/s44276-026-00230-0","DOIUrl":"10.1038/s44276-026-00230-0","url":null,"abstract":"","PeriodicalId":519964,"journal":{"name":"BJC reports","volume":"4 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13261152/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148230370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improving cancer care while reducing its carbon footprint: GHG-mitigating strategies highlighted at ESMO 2025.","authors":"Matthieu Delaye, Paul Matte, Anthony Turpin, Coline Ducrot, Sarah Dumont, Pierre-Florent Petit, Max Piffoux","doi":"10.1038/s44276-026-00231-z","DOIUrl":"10.1038/s44276-026-00231-z","url":null,"abstract":"<p><strong>Background: </strong>The environmental impact of cancer care is an emerging concern, yet therapeutic strategies that may incidentally reduce greenhouse gas (GHG) emissions remain poorly described. The 2025 ESMO Congress, where nearly 3000 abstracts were presented, offered an opportunity to identify clinically validated approaches that could lower the carbon footprint of oncology.</p><p><strong>Methods: </strong>All abstracts from the 2025 ESMO Congress were reviewed. Studies suggesting meaningful downstream reductions in drug use, visit frequency, treatment duration, or overall care intensity were selected. For each, GHG emissions were estimated using the ECOVAMED drug carbon-footprint database and standard emission factors.</p><p><strong>Results: </strong>Ten abstracts were identified. They spanned primary prevention, therapeutic de-escalation, reduced dose or duration of systemic therapy, biomarker-guided treatment selection, and non-pharmacological interventions. Several strategies demonstrated non-inferior or improved clinical outcomes while substantially lowering treatment-related emissions. Notably, none of the selected studies had explicitly assessed environmental impact.</p><p><strong>Conclusions: </strong>Multiple strategies presented at ESMO 2025 appear capable of improving patient outcomes while reducing the environmental burden of cancer care. Systematically integrating environmental endpoints into clinical research would help identify such win-win approaches and advance a more sustainable oncology practice.</p>","PeriodicalId":519964,"journal":{"name":"BJC reports","volume":"4 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13260991/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148230354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Contralateral breast cancer risks for BRCA1, BRCA2, PALB2, CHEK2, and ATM pathogenic variant carriers in two large cohort studies.","authors":"Isaac Allen, Nancy Whish, Siddhartha Yadav, Nicholas J Boddicker, Caroline Drukker, Irma van de Beek, Diana M Eccles, Clare Turnbull, Paul Pharoah, Antonis C Antoniou, Douglas F Easton, Fergus J Couch, Marjanka K Schmidt, Marc Tischkowitz","doi":"10.1038/s44276-026-00220-2","DOIUrl":"10.1038/s44276-026-00220-2","url":null,"abstract":"<p><strong>Background: </strong>All breast cancer (BC) patients have a risk of developing contralateral BC (CBC). This will be higher in women carrying a BC susceptibility gene pathogenic variant (PV), but specific risk estimates are lacking. We addressed this in a study-level meta-analysis of two large, recent cohort studies that used Breast Cancer Risk after Diagnostic Gene Sequencing (BRIDGES) project and Cancer Risk Estimates Related to Susceptibility (CARRIERS) consortium data.</p><p><strong>Methods: </strong>We used population risks from the Netherlands to estimate 10-year cumulative CBC risks for BRCA1, BRCA2, PALB2, CHEK2, and ATM PV carriers. We estimated pooled hazard ratios (HRs) in meta-analyses using the generic inverse-variance method and assuming random effects. We stratified by first BC estrogen receptor (ER) status.</p><p><strong>Results: </strong>Among 462 BRCA1, 590 BRCA2, 796 CHEK2, 297 PALB2, and 345 ATM PV carriers, we estimated 10-year cumulative CBC risks of 10.1% (95% confidence interval (CI):7.5-13.6%) for BRCA1, 10.2% (95%CI:7.4-13.9%) for BRCA2, 7.1% (95%CI:3.4-14.3%) for PALB2, 8.0% (95%CI:5.7-11.1%) for CHEK2 (any PV), 8.5% (95%CI:5.9-12.3%) for CHEK2 del.1100 C, and 4.5% (95%CI:2.5-8.0%) for ATM PV carriers. We found elevated HRs in BRCA1 (HR:2.8, 95%CI:2.1-3.6), BRCA2 (HR:2.8, 95%CI:2.1-3.7), and CHEK2 PV carriers (all PVs: HR:2.1, 95%CI:1.6-2.9. del.1100 C PVs only: HR:2.3, 95%CI:1.6-3.3). We found no significantly elevated risks in PALB2 (HR:1.9, 95%CI:0.9-3.8) or ATM (HR:1.2, 95%CI:0.7-2.1) PV carriers. We saw increased risks in BRCA1/2 and CHEK2 PV carriers following ER-positive BC, and in BRCA1/2 and PALB2 PV carriers following ER- negative BC.</p><p><strong>Conclusion: </strong>BC survivors carrying BRCA1, BRCA2, and CHEK2 PVs and ER-negative BC survivors carrying PALB2 PVs are at two-fold or higher CBC risks. These estimates may assist clinical decision making for management of the contralateral breast.</p>","PeriodicalId":519964,"journal":{"name":"BJC reports","volume":"4 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13234405/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148160327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}